Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Tomlins SA et al. – Ongoing work suggests that the discovery of E twenty–six (ETS) gene fusions in prostate cancer can be translated to clinical practice. Likely areas of impact include early detection, diagnosis, treatment decisions, and therapeutic targeting.

Related Articles

Fusion genes and chromosome translocations in the common epithelial cancers
The Journal of Pathology, 11/20/09    Relevance Score: 70%

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
Annals of Surgical Oncology, 11/25/09    Relevance Score: 68%

Contribution of Matrix, Fusion, Hemagglutinin, and Large Protein Genes of the CAM-70 Measles Virus Vaccine Strain to Efficient Growth in Chicken Embryonic Fibroblasts
Journal of Virology, 10/26/09    Relevance Score: 68%

Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck
Proceedings of the National Academy of Sciences of the United States of America, 11/04/09    Relevance Score: 67%

Detection and Clinical Relevance of BCR-ABL Fusion Gene in Childhood T-lineage Acute Lymphoblastic Leukemia
Journal of Pediatric Hematology/Oncology, 11/30/09    Relevance Score: 66%

Today in Basic Science/Genetics...keeping you current

Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study
Journal of Cancer Research & Clinical Oncology, 12/04/09

Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
The Prostate, 12/04/09

DNA repair gene polymorphisms and prostate cancer risk in South Australia--results of a pilot study
Urologic Oncology: Seminars and Original Investigations, 12/03/09

Today in Oncology...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09

The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address